Rodman & Renshaw begins Novavax coverage

Novavax, Inc. coverage was initiated by Rodman & Renshaw, LLC analyst Navdeep Jaikaria at a market outperform rating and a $6 price target. Shares of the Malvern, Pa., pharmaceutical company were up 26 cents, or 7.60%, at $3.68 on volume of 9,927,205 shares versus the three-month running average of 9,513,560 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.